The C.D.C. said that Paxlovid “continues to be recommended for early-stage treatment of mild to moderate Covid-19 among persons at high risk for progression to severe disease.” The Food and Drug Administration authorized Paxlovid for high-risk people age 12 and older who weigh at least 88 pounds.
